Moolec Science SA MLEC

Moolec Science SA successfully completes its 2026 GLASO commercial planting campaign in the United States. Successful completion of the GLASO planting campaign advances Moolec's commercialization timeline and strengthens production capabilities.

Moolec Science SA (MLEC) has regained compliance with all Nasdaq Capital Market continued listing requirements within the designated panel remediation period, avoiding potential delisting. Regaining Nasdaq compliance eliminates delisting risk, stabilizing operations and boosting investor sentiment significantly.

Moolec Science SA confirms completion of first phase of GLASO industrialization after record 2025 campaign, advances 2026 sowing, and expands into energy applications. Completion of GLASO industrialization phase after record campaign advances commercialization, supports future sowing, and opens energy market opportunities.

Moolec Science SA announces breakthrough in molecular farming: successful expression of bovine myoglobin—a key meat protein—in pea seeds, advancing plant-based production of animal proteins. Achieving functional expression of bovine myoglobin in plants validates Moolec's molecular farming platform, enabling scalable, sustainable meat proteins and significantly enhancing competitive edge and investor sentiment.

Moolec Science SA has achieved one of the highest commercial-scale concentrations of GLA from its U.S. GLASO1 crushing process. This milestone is expected to enhance the company's product offerings and strengthen its position in the market for plant-based proteins and ingredients. Achieving high GLA concentrations could significantly enhance product competitiveness and market positioning.

Moolec Science SA (MLEC) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market positioning have contributed to its visibility among investors, indicating potential shifts in market dynamics. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.

Moolec Science SA has been granted continued listing on Nasdaq, contingent upon conditions set by a hearings panel. This decision comes after the company faced potential delisting due to non-compliance with Nasdaq's listing standards. Moolec is now required to meet specific criteria to maintain its listing status. Continued listing on Nasdaq is crucial for Moolec's market presence and investor confidence, but the impact is moderated by the need to meet ongoing compliance requirements.

Moolec Science S.A. has received a memo from Nasdaq staff granting an exception until June 29, 2026, to regain compliance with the stockholders' equity requirement. This decision provides the company with additional time to meet the necessary financial criteria to maintain its listing on the exchange. The extension allows Moolec Science to stabilize its financial position, potentially influencing its market performance.

Moolec Science S.A. has been granted an exception by a Nasdaq panel, allowing the company until June 29, 2026, to regain compliance with the stockholders' equity requirement. This decision provides Moolec with additional time to improve its financial standing and meet the necessary criteria for continued listing on the Nasdaq exchange. The extension allows Moolec to address its financial compliance, which may influence its market position but does not guarantee significant changes.

Moolec Science SA announced the effectiveness of its share consolidation, which is aimed at enhancing the company's capital structure and potentially improving its market perception. The consolidation is expected to streamline the share count and may attract more institutional investors, thereby increasing liquidity and stability in the stock price. This strategic move aligns with the company's long-term goals of growth and innovation in the plant-based protein sector. Share consolidation can moderately influence market perception and investor interest, but its overall impact on the company's trajectory is expected to be limited.

Moolec Science SA has received a Staff Determination Letter from Nasdaq regarding its compliance status with listing requirements. The company is currently evaluating its options to regain compliance and has provided an update on its efforts to meet the necessary criteria for continued listing on the exchange. The compliance status with Nasdaq could moderately influence Moolec's market perception and operational focus.

Moolec Science SA has announced a share consolidation of its ordinary shares, with a par value of U.S.$0.10 per share. This move is part of the company's strategy to enhance its capital structure and potentially improve its market perception. The consolidation will reduce the number of outstanding shares, which may lead to an increase in the share price. Share consolidation can moderately influence market perception and financial metrics, but its overall impact on long-term performance remains limited.

Moolec Science SA (MLEC) has announced the scaling of its GLASO U.S. platform with a record campaign for 2025, alongside an expansion into the nutrition and supplements market. This strategic move aims to enhance its product offerings and market presence, tapping into the growing demand for innovative nutritional solutions. The expansion into the nutrition and supplements market represents a significant strategic move that could alter the company's trajectory and investor sentiment.

Moolec Science SA received a determination letter from Nasdaq indicating that it no longer meets the minimum bid price requirement for continued listing. The company has a 180-day grace period to regain compliance by maintaining a minimum bid price of $1 per share for at least ten consecutive trading days. Moolec is evaluating its options to address this issue and remains committed to maintaining its listing on Nasdaq. The determination letter indicates a compliance issue that could affect investor sentiment and market performance.

Moolec Science SA received a determination letter from Nasdaq indicating that it no longer meets the minimum bid price requirement for continued listing. The company has a 180-day grace period to regain compliance by achieving a minimum bid price of $1 per share for at least ten consecutive trading days. Moolec is evaluating its options to address this issue and maintain its listing status. The determination letter indicates a compliance issue that could affect investor sentiment and market performance.

Moolec Science SA has received regulatory approval for its Safflower GLASO technology in Argentina, allowing for expanded operations in the region. Additionally, the company is increasing its U.S. acreage to enhance production capabilities. To further strengthen its leadership team, Moolec has appointed a new Chief Financial Officer. Regulatory approval and expansion of U.S. acreage are significant strategic moves that could enhance Moolec's market position and investor sentiment.

Moolec Science Limited has received a Notice of Allowance from the USPTO for its Piggy Sooy™ technology, a soybean engineered to express high levels of porcine hemeproteins. This patent grants exclusive commercial rights in the U.S. until 2042 and covers the plants, seeds, and food compositions derived from this innovation. The USDA-APHIS confirmed that Piggy Sooy™ poses no plant pest risk, facilitating its path to commercialization. Initial trials showed over 20% animal protein content, with significant environmental benefits compared to traditional meat production. Moolec aims to secure a robust intellectual property portfolio with over fifteen global patent applications related to its Molecular Farming innovations. The patent approval and environmental advantages of Piggy Sooy™ are likely to significantly impact Moolec's market positioning and commercialization strategy.

Moolec Science SA has successfully completed its business combination, which is expected to enhance its presence in the life sciences and food-tech sectors. This strategic move aims to leverage synergies between the two industries, positioning the company for growth and innovation in developing sustainable food solutions. The business combination is a major strategic move that could significantly alter the company's trajectory and investor sentiment.

Moolec Science SA has entered into a Business Combination Agreement with Bioceres Group and related entities in an all-stock transaction, expanding its corporate structure. Moolec will issue up to 87 million shares and 5 million warrants to shareholders of the Contributed Entities, enhancing its position in the agricultural value chain. The transaction aims to integrate technologies for sustainable agricultural solutions and is expected to close in the second quarter of 2025, pending shareholder approval. Key executives from both companies expressed optimism about the potential for innovation and growth in the bioeconomy. The Business Combination is a significant strategic move that could enhance Moolec's market position and innovation capabilities in agriculture.

Moolec Science SA received a Nasdaq Determination Letter on March 11, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) due to its stock price remaining below $1.00 for over 30 consecutive business days. The company is not eligible for a second compliance period as it does not meet the minimum stockholders' equity requirement. Moolec has appealed the determination and plans to execute a reverse share split to regain compliance. An extraordinary shareholders meeting will be convened to vote on this matter. The appeal stays any potential delisting pending a hearing. The appeal and proposed reverse share split are significant strategic moves that could alter the company's market position and investor sentiment.

Moolec Science SA is eyeing the vegetarian market with beef-infused peas, awaiting FDA approval for consumption. The potential launch of the GMO peas could significantly alter Moolec's trajectory and market positioning.

Moolec Science SA has received USDA approval for the first genetically modified pea in history, marking a significant milestone for the company. The approval of the genetically modified pea has the potential to revolutionize the food ingredient market and the pea industry, positioning Moolec for significant impact on future performance.

Moolec Science reported a US$0.19 loss per share for FY 2024, with revenue increasing by US$55.3m from FY 2023. The financial results show a widened net loss and expected revenue decline, impacting the company's future performance.

Moolec Science reported its Business Update for the fourth quarter of Fiscal Year 2024, highlighting advancements in GLASO™, Piggy Sooy™, and TSP Valorasoy™, as well as financial performance. The article discusses significant advancements in product development and financial performance that are expected to have a major impact on Moolec Science's future.

Moolec Science SA will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on October 2, 2024, followed by a live Conference Call hosted by the company's executives. The announcement of the Business Update and Conference Call is a significant event that could impact Moolec Science SA's future performance and market sentiment.

Moolec received a Nasdaq Bid Price Letter due to its shares trading below $1.00 for 30 consecutive days, with a 180-day compliance period to regain compliance. The notification may moderately influence Moolec's financial performance and market sentiment, but the overall effect is expected to be somewhat limited.

Moolec Science SA confirms US harvest for plant-grown products GLASO™ and Piggy Sooy™ in October 2024. The article describes significant developments in Moolec's product launches and regulatory approvals that could alter the company's trajectory.

Moolec Science SA signs offtake agreement with major global CPG company for GLASO™ nutritional oil product, targeting US market in 2025. The agreement signifies a significant step in commercializing Moolec's flagship technology and expanding its market presence.

Moolec Science SA provided a business update for the third quarter of Fiscal Year 2024, highlighting progress on Piggy Sooy™ and GLASO™ platforms. The article mentions significant achievements such as USDA-APHIS approval and progress in commercial production streams, which could have a major impact on the company's trajectory and market sentiment.

Moolec Science SA to release Business Update for Third Quarter Fiscal Year 2024 and host conference call with executives. The announcement of the Business Update and conference call is a significant event that could impact Moolec Science SA's future performance and market sentiment.